ZCA
MRTX

Zeke Capital Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Zeke Capital Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,801
Closed -$264K – 533
2021
Q4 		$264K Buy
+1,801
New +$280K 0.02% 250

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Zeke Capital Advisors's MRTX Position: Q1 2022 in Review

Zeke Capital Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022, closing a stake of 1,801 shares — an estimated $264K sold.

Zeke Capital Advisors first reported a position in MRTX in Q4 2021 and held it in 1 quarter. The position peaked at $264K in Q4 2021. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

  • Zeke Capital Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Zeke Capital Advisors sold 1,801 Mirati Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $264K.
  • Zeke Capital Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Zeke Capital Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $264K in Q4 2021.
  • 253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Zeke Capital Advisors's 13F filing for Q1 2022, filed 13 May 2022.